BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33677616)

  • 1. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
    Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
    Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
    Li H; Xu Q; Wang Y; Chen K; Li J
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
    Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
    Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing and Managing Toxicities of High-Dose Methotrexate.
    Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
    Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
    Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
    Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
    Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
    Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
    Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
    Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
    Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,4-Diamino-N10-methylpteroic acid (DAMPA) crystalluria in a patient with osteosarcoma treated with carboxypeptidase-G2 rescue after high-dose methotrexate-induced nephrotoxicity.
    Berga F; Luna P; Martorell C; Rey J; Gomila I; Gimenez S; Costa-Bauza A; Elorza MÁ; Sánchez I; Grases F; Barceló B
    Clin Chim Acta; 2018 Dec; 487():1-5. PubMed ID: 30205081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.